Mesoblast Ltd ADR
Mesoblast Ltd ADR (MESO) Unusual Options Activity Today
MESO options volume power reached 6.2x on the previous trading day. The highest reading was on the $16 PUT expiring 2027-04-16.
Read more
Checking MESO unusual options activity helps you spot when traders are making outsized bets on Mesoblast Ltd ADR before the broader market catches on. Mesoblast Ltd ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor MESO unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching MESO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking MESO unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and MESO unusual options flow data becomes especially valuable around earnings, product launches, and macro events.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Catalysts rarely arrive without a footprint, and MESO unusual options activity is often where that footprint shows up first. Our scanner tracks Mesoblast Ltd ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at MESO unusual options volume on the call side or chasing put sweeps, Mesoblast Ltd ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.
| 3.00 | 9.00 | 13.90 | 11.45 | 90% | 0 | 0 | — |
| 5.00 | 7.00 | 11.90 | 9.45 | 52% | 0 | 0 | — |
| 9.00 | 3.00 | 8.00 | 5.50 | 19% | 0 | 0 | — |
| 10.00 | 2.10 | 7.00 | 4.55 | 92% | 0 | 200 | 0.00% |
| 11.00 | 1.10 | 6.00 | 3.55 | 70% | 0 | 0 | — |
| 3.00 | — | 5.00 | 5.00 | 1,000% | 0 | 0 | — |
| 5.00 | — | 5.00 | 5.00 | 1,000% | 0 | 0 | — |
| 9.00 | — | 5.00 | 5.00 | 840% | 0 | 0 | — |
| 10.00 | — | 5.00 | 5.00 | 734% | 0 | 0 | — |
| 11.00 | — | 5.00 | 5.00 | 645% | 0 | 0 | — |
As of September 28, 2026
Spot unusual options activity before it moves
Track MESO options flow across every expiration, filter by volume power, and find the setups with abnormal activity before the trade is gone.
Start your 14-day free trial→